Prevention by the 5-HT3 receptor antagonist, ondansetron, of morphine-dependence and tolerance in the rat

S C Hui, E L Sevilla, C W Ogle, S C Hui, E L Sevilla, C W Ogle

Abstract

1. The effect of ondansetron, a selective 5-hydroxytryptamine3 (5-HT3) receptor antagonist, was studied in morphine-addicted rats. Morphine-dependence and tolerance, induced by drinking increasing concentrations of morphine sulphate in 5% sucrose solution for 3 weeks, were demonstrated by the naloxone-precipitated withdrawal syndrome and tail flick response to a thermal noxious stimulus (water at 50 degrees C), respectively. 2. Morphine-dependence, assessed by naloxone precipitated withdrawal, was undetectable by the 6th day, when the animals drank only tap water for 7 days after the 3-week induction period. 3. When detoxified rats were offered sucrose and morphine solutions for 10 days, the recurrence of opiate solution preference with relapse to dependence and tolerance was observed. 4. Giving ondansetron (0.1 or 1 microgram kg-1; i.p.; twice daily) on the 14th day of, or 7 days prior to, the 3-week induction period reduced dependence and tolerance seen during the 3-week morphine induction and the 10-day drinking preference periods. 5. 5-Hydroxytryptamine2 (5-HT2) receptor antagonism by cyproheptadine (100 or 250 micrograms kg-1; i.p.; twice daily) did not influence morphine-dependence and tolerance. 6. These findings suggest that ondansetron may be useful for treating opiate addiction and lowering the recidivism rate.

References

    1. Eur J Pharmacol. 1987 Jun 19;138(2):303-5
    1. Neuropharmacology. 1986 Jun;25(6):563-76
    1. Br J Pharmacol. 1987 Dec;92(4):881-94
    1. Nature. 1974 May 31;249(456):471-3
    1. Life Sci. 1981 Nov 2;29(18):1881-6
    1. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
    1. Br J Pharmacol. 1988 Jun;94(2):397-412
    1. Eur J Pharmacol. 1988 Jun 22;151(1):159-60
    1. Eur J Pharmacol. 1988 Oct 18;155(3):349-50
    1. Pharmacol Biochem Behav. 1989 Dec;34(4):769-78
    1. Pharmacol Biochem Behav. 1990 May;36(1):97-104
    1. Pharmacol Biochem Behav. 1990 Jun;36(2):339-44
    1. J Neurosci. 1991 Jul;11(7):1881-8
    1. Psychopharmacology (Berl). 1992;106(3):315-20
    1. Eur J Pharmacol. 1992 Oct 20;221(2-3):227-34
    1. Br J Pharmacol. 1993 Dec;110(4):1341-6
    1. Br J Pharmacol. 1982 Mar;75(3):485-91
    1. Psychopharmacology (Berl). 1983;79(2-3):278-83
    1. Pharmacol Res Commun. 1984 May;16(5):495-511
    1. Pharmacol Biochem Behav. 1985 Nov;23(5):843-9
    1. Pharmacol Biochem Behav. 1985 Dec;23(6):1029-36
    1. Nature. 1987 Dec 24-31;330(6150):746-8

Source: PubMed

Подписаться